Aripiprazole use combined with depot antipsychotic medication: Two cases demonstrating its ability to reduce prolactin levels in an adolescent forensic hospital

Therapeutic Advances in Psychopharmacology

Volumn 1, Issue 3, 2011, Pages 77-79

  Hill, Simon A ^a   Khan, al Aditya ^a   Wetherill, Marion ^b  

^a Consultant Forensic Psychiatrist ^*  (United Kingdom)

^b Locality Lead Pharmacist   (United Kingdom)

Author keywords

antipsychotic; aripiprazole; forensic; hyperprolactinaemia; polypharmacy; prolactin

Indexed keywords

ARIPIPRAZOLE; NEUROLEPTIC AGENT; OLANZAPINE; PROLACTIN; RISPERIDONE; ZUCLOPENTHIXOL DECANOATE;

ADOLESCENT; ADULT; ARTICLE; CASE REPORT; DRUG INDUCED DISEASE; EJACULATION DISORDER; FORENSIC SCIENCE; GYNECOMASTIA; HUMAN; HYPERPROLACTINEMIA; MALE; PENIS ERECTION; POLYPHARMACY; PRIORITY JOURNAL; PSYCHOSIS; SEXUAL FUNCTION; VIOLENCE;

EID: 84997943787     PISSN: 20451253     EISSN: 20451261     Source Type: Journal    
DOI: 10.1177/2045125311409284     Document Type: Article

References (21)

1. Adan-Manes J. Garcia-Parajua P. (2009) Aripiprazole in combination with other antipsychotic drugs may worsen psychosis. J Clin Pharm Ther 34: 245–246.
2. Anderson J. The interface with forensic services. In: Beer M.D. Pereira S. Paton C. (Eds.) (2008) Psychiatric Intensive Care 2nd. Cambridge: Cambridge University Press, 191–201.
3. Barnes T.R.E. Shingleton-Smith A. Paton C. (2009) Antipsychotic long-acting injections: Prescribing practice in the UK. Br J Psychiatry 195: S37–S42.
4. Boyd A. (1995) Bromocriptine and psychosis: A literature review. Psychiatr Q 66: 87–95.
5. Casanueva F.F. Molitch M.E. Schlechte J.A. Abs R. Bonert V. Bronstein M.D. et al. (2006) Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. Clin Endocrinol 65: 265–273.
6. Finn, S.E., Bailey, J.M., Schultz, R.T., Faber, R. (1990) Subjective utility ratings of neuroleptics in treating schizophrenia. Psychological Medicine 20: 843–848.
7. Halbreich U. Kinon B.J. Gilmore J.A. Kahn L.S. (2003) Elevated prolactin levels in patients with schizophrenia: mechanisms and related adverse effects. Psychoneuroendocrinology 28(Suppl 1): 53–67.
8. Henderson D.C. Fan X. Copeland P.M. Sharma B. Borba C.P. Boxill R. et al. (2009) Aripiprazole added to overweight and obese olanzapine-treated schizophrenia patients. J Clin Psychopharmacol 29: 165–169.
9. Hoffer Z.S. Roth L.R. Mathews M. (2009) Evidence for the partial dopamine-receptor agonist aripiprazole as a first-line treatment of psychosis in patients with iatrogenic or tumorogenic hyperprolactinemia. Psychosomatics 50: 317–324.
10. Kuo J. Hwu H. (2008) Aripiprazole and Haloperidol: beneficial combination antipsychotic therapy for a schizophrenic patient. Clin Neuropharmacol 31: 173–175.
11. Langan J. Shajahan P. (2010) Antipsychotic polypharmacy: a review of mechanisms, mortality and management. Psychiatrist 34: 58–62.
12. Lehman A.F. Lieberman J.A. Dixon L.B. McGlashan T.H. Miller A.L. Perkins D.O. et al. (2004) Practice guideline for the treatment of patients with schizophrenia. 2nd edn. Am J Psychiatry 161(Suppl.): 1–56.
13. Lorenz R.A. Weinstein B. (2007) Resolution of haloperidol-induced hyperprolactinaemia with aripiprazole. J Clin Psychopharmacol 27: 524–552.
14. Maguire G.A. (2002) Prolactin elevation with antipsychotic medications: mechanisms of action and clinical consequences. J Clin Psychiatry 63(Suppl. 4): 56–62.
15. Marden S. McQuade R. Stock E. Kaplita S. Marcus R. Safferman A. et al. (2003) Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophr Res 61: 123–136.
16. Markianos M. Hatzimanolis J. Lykouras L. (2001) Neuroendocrine responsivities of the pituitary dopamine system in male schizophrenic patients during treatment with clozapine, olanzapine, risperidone, sulpiride or haloperidol. Eur Arch Psychiatry Clin Neurosci 251: 141–146.
17. Moore T.A. Buchanan R.W. Buckley P.F. Chiles J.A. Conley R.R. Crismon M.L. et al. (2007) The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2006 update. J Clin Psychiatry 68: 1751–1762.
18. National Institute for Health and Clinical Excellence (2009) Schizophrenia: core interventions. in the treatment and management of schizophrenia in adults in primary and secondary care (update). NICE Clinical Guideline 82–82.
19. Petty R.G. (1999) Prolactin and antipsychotic medications: Mechanism of action. Schizophr Res 35(Suppl. 1): S67–S73.
20. Shim J.C. Shin J.G. Kelly D.L. Jung D.U. Seo Y.S. Liu K.H. (2007) Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic induced hyperprolactinaemia: a placebo-controlled trial. Am J Psychiatry 164: 1404–1410.
21. Taylor D. (2010) Antipsychotic polypharmacy: confusion reigns. Psychiatrist 34: 41–43.